Three additional product patents in the US for HyNap-Dasa
Press release 2020-02-18
STOCKHOLM – February 18, 2020. Xspray Pharma (Nasdaq First North Growth Market: XSPRAY) announces that the United States Patent and Trademark Office (USPTO) has granted Xspray three new US patent for HyNap-Dasa. The new patents, US10,561,643; US 10,561,644; and US10,561,645, are valid until January 2033. This means that Xspray now has seven product patents for the pharmaceutical composition of the company's primary product candidate, HyNap-Dasa, in the company's main market USA.
“With a total of seven patents for HyNap-Dasa in our most important market, we can justifiably state that it will be extremely difficult for other players to launch a dasatinib product based on amorphous solid dispersion in the United States during the lifetime of the patent, ie until January 2033. This is undoubtably very important for our potential partners,” says Per Andersson, CEO of Xspray.
Xspray strives to obtain patents for both composition and technology and these new patents claim an amorphous solid dispersion (pharmaceutical composition) of dasatinib.
For more information, please contact:
Per Andersson, CEO, Xspray Pharma AB
Phone: +46 (0) 706 88 23 48
About Xspray Pharma
Xspray Pharma AB (publ) is a product development company with multiple product candidates in clinical development. Xspray uses its innovative, patented RightSize technology to develop improved and generic versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. The segment is the second largest in oncology, and drug prices are very high.
The company´s innovative technology allows Xspray Pharma to gain entry as the first competitor to today’s original drugs before the secondary patents expire. Xspray’s goal is to become the leader in the development of improved drugs or generic versions of PKIs already marketed for the treatment of cancer, which numbered to 54 in December 2019. The company’s leading product candidates, HyNap-Dasa, HyNap-Sora and HyNap-Nilo, are stable amorphous versions of the three blockbuster cancer drugs Sprycel® (dasatinib), Nexavar® (sorafenib) and Tasigna® (nilotinib), respectively. The launch of the first product candidate, HyNap-Dasa, is planned to take place in 2021. The substance patent for the original drug Sprycel® (dasatinib) expires at the end of 2020, and the secondary patents in 2026, which offers Xspray’s HyNap-Dasa a period of five years of semi-exclusivity before other competitors gain access to the market.
The company has patented manufacturing technology, equipment and the resulting products. The shares in Xspray Pharma are traded on Nasdaq First North Growth Market Stockholm.
Redeye AB is Xspray Pharma’s Certified Adviser
+46 (0) 8 121 576 90
The information was submitted for publication, through the agency of the contact person set out above, at 2.00 p.m. CET on February 18, 2020.